Pyxis Oncology is trading at $3.56, down 5.07% after reversing an early biotech-led rally.
- No new company-specific announcement, earnings release, or regulatory catalyst was identified on September 3, 2026.
- The latest company update concerns upcoming investor conferences, not an operational development.
- Broader equities and biotech are higher, so sector momentum does not explain the decline; the reversal follows two consecutive daily gains of 9.01% and 6.17%.